Eiger BioPharmaceuticals (STU:72C) Scaled Net Operating Assets: 0.02 (As of Dec. 2023)

What is Eiger BioPharmaceuticals Scaled Net Operating Assets?

Eiger BioPharmaceuticals STU:72C 10 Scaled Net Operating Assets is 0.02 as of Dec. 2023. GuruFocus rates STU:72C with a GF Score™ of 10/100.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Eiger BioPharmaceuticals's operating assets for the quarter that ended in Dec. 2023 was €12.28 Mil. Eiger BioPharmaceuticals's operating liabilities for the quarter that ended in Dec. 2023 was €11.08 Mil. Eiger BioPharmaceuticals's Total Assets for the quarter that ended in Jun. 2023 was €66.79 Mil. Therefore, Eiger BioPharmaceuticals's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was 0.02.

Eiger BioPharmaceuticals Scaled Net Operating Assets Related Terms

Eiger BioPharmaceuticals Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Eiger BioPharmaceuticals's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eiger BioPharmaceuticals Scaled Net Operating Assets Chart

Eiger BioPharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Scaled Net Operating Assets

Get a 7-Day Free Trial

-0.06

-0.01

0.12

-0.03

0.01

Eiger BioPharmaceuticals Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Scaled Net Operating Assets	Get a 7-Day Free Trial															0.00	-0.02	0.02	0.02	-0.14

STU:72C vs EDSA, SIGY, EVLO: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Eiger BioPharmaceuticals's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eiger BioPharmaceuticals Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eiger BioPharmaceuticals's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Eiger BioPharmaceuticals's Scaled Net Operating Assets falls into.

Save Embed

10GF Score

Eiger BioPharmaceuticals Inc STU:72C

Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Eiger BioPharmaceuticals Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Eiger BioPharmaceuticals's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2023 )
=	(Operating Assets (A: Dec. 2023 )	-	Operating Liabilities (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2022 )
=	(12.275	-	11.078)	/	113.411
=	0.01

where

	Operating Assets		(A: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	35.603	-	23.328
=	12.275

	Operating Liabilities		(A: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	48.861	-	0	-	37.783
=	11.078

Eiger BioPharmaceuticals's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Dec. 2023 )
=	(Operating Assets (Q: Dec. 2023 )	-	Operating Liabilities (Q: Dec. 2023 ))	/	Total Assets (Q: Jun. 2023 )
=	(12.275	-	11.078)	/	66.786
=	0.02

where

	Operating Assets		(Q: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	35.603	-	23.328
=	12.275

	Operating Liabilities		(Q: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	48.861	-	0	-	37.783
=	11.078

Frequently Asked Questions Learn more about Scaled Net Operating Assets →

What does a Scaled Net Operating Assets of 0.02 mean?

Eiger BioPharmaceuticals (STU:72C) has a Scaled Net Operating Assets of 0.02 as of Dec. 2023. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Eiger BioPharmaceuticals and its competitors.

Is Eiger BioPharmaceuticals' Scaled Net Operating Assets too high?

Eiger BioPharmaceuticals' current Scaled Net Operating Assets is 0.02. Overall, Eiger BioPharmaceuticals has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.

How does Eiger BioPharmaceuticals' Scaled Net Operating Assets compare to EDSA and SIGY?

Eiger BioPharmaceuticals' Scaled Net Operating Assets of 0.02 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Scaled Net Operating Assets for a Biotechnology company?

A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Scaled Net Operating Assets mean?

A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Eiger BioPharmaceuticals and its competitors. Eiger BioPharmaceuticals's current Scaled Net Operating Assets is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Eiger BioPharmaceuticals stock overvalued right now?

Eiger BioPharmaceuticals (STU:72C) has a current Scaled Net Operating Assets of 0.02. The current Scaled Net Operating Assets is 0.02. Eiger BioPharmaceuticals' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Scaled Net Operating Assets calculated?

Scaled Net Operating Assets is calculated from a company's financial statements. For Eiger BioPharmaceuticals (STU:72C), the current Scaled Net Operating Assets is 0.02 as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eiger BioPharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies EDSA SIGY EVLO GTBP IMNN NHWK TMBR GRTX CMRA ONVO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX

Address 2155 Park Boulevard, Palo Alto, CA, USA, 94306

Website https://www.eigerbio.com

Eiger BioPharmaceuticals Inc is a commercial stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.

10GF Score

Get the complete analysis for STU:72C

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.18

Price

View STU:72C Analysis

See Scaled Net Operating Assets data for all stocks →